The French healthcare sector
Healthcare spending in France is the second highest share (12.3% of GDP) in the EU after Germany. The size of the French healthcare sector (€90 billion), the universal healthcare system and massive government investments make the country attractive to Swiss medical and pharmaceutical companies.
Marketing and access to reimbursement
Marketing authorization (AMM) is granted after the evaluation of pharmaceutical quality, efficacy, safety (adverse effects) and risk-benefit ratio by the European and French Medical Agencies. AMM and registration are granted for an initial period of 5 years. The HAS Transparency Commission evaluates medical services rendered and the improvement in medical services rendered with a view to reimbursement.
Gain an understanding of the market access conditions and channels for Swiss healthcare companies by reading our industry report below.
